Cubist Systematic Strategies LLC Boosts Position in CryoPort, Inc. $CYRX

Key Points

• Cubist Systematic Strategies LLC increased its holdings in CryoPort, Inc. by 109.6%, owning 226,457 shares valued at $1.38 million, according to recent SEC disclosures.
• CEO Jerrell Shelton and CFO Robert Stefanovich sold shares of CryoPort, reducing their ownership by 1.76% and 4.30%, respectively, with insiders selling a total of 486,625 shares in the past 90 days.
• Analysts have shown optimism for CryoPort, with ratings such as "overweight" and "strong-buy," and an average price target of $12.00 following recent upgrades from various research firms.

Cubist Systematic Strategies LLC lifted its position in shares of CryoPort, Inc. (NASDAQ:CYRX - Free Report) by 109.6% during the first quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 226,457 shares of the company's stock after buying an additional 118,420 shares during the period. Cubist Systematic Strategies LLC owned about 0.45% of CryoPort worth $1,377,000 as of its most recent SEC filing.

Other institutional investors and hedge funds have also bought and sold shares of the company. Rhumbline Advisers grew its position in CryoPort by 23.8% during the 1st quarter. Rhumbline Advisers now owns 78,320 shares of the company's stock worth $476,000 after acquiring an additional 15,036 shares during the last quarter. Russell Investments Group Ltd. grew its position in shares of CryoPort by 154.5% in the 1st quarter. Russell Investments Group Ltd. now owns 32,761 shares of the company's stock worth $199,000 after buying an additional 19,886 shares during the last quarter. Graham Capital Management L.P. boosted its position in shares of CryoPort by 24.9% during the fourth quarter. Graham Capital Management L.P. now owns 28,460 shares of the company's stock valued at $221,000 after purchasing an additional 5,667 shares in the last quarter. Lazard Asset Management LLC bought a new stake in shares of CryoPort during the fourth quarter valued at approximately $51,000. Finally, ProShare Advisors LLC bought a new stake in shares of CryoPort during the fourth quarter valued at approximately $95,000. 92.90% of the stock is currently owned by institutional investors.

Analyst Ratings Changes

Several research firms recently weighed in on CYRX. Stephens began coverage on CryoPort in a research report on Tuesday, July 22nd. They set an "overweight" rating and a $13.00 price target on the stock. KeyCorp upgraded CryoPort from a "sector weight" rating to an "overweight" rating and set a $15.00 price target on the stock in a research report on Wednesday, August 6th. Leerink Partners upgraded CryoPort from a "market perform" rating to an "outperform" rating and set a $16.00 price target on the stock in a research report on Wednesday, August 6th. BTIG Research dropped their price target on CryoPort from $13.00 to $10.00 and set a "buy" rating on the stock in a research report on Monday, July 7th. Finally, Leerink Partnrs upgraded CryoPort from a "hold" rating to a "strong-buy" rating in a research report on Wednesday, August 6th. One research analyst has rated the stock with a Strong Buy rating, eight have assigned a Buy rating and one has assigned a Hold rating to the stock. Based on data from MarketBeat, the stock currently has an average rating of "Buy" and a consensus price target of $12.00.

CryoPort Stock Down 8.8%

Shares of CYRX stock traded down $0.83 during mid-day trading on Friday, hitting $8.64. The company's stock had a trading volume of 1,081,340 shares, compared to its average volume of 518,306. CryoPort, Inc. has a 52-week low of $4.58 and a 52-week high of $10.46. The business has a 50-day moving average price of $8.23 and a 200 day moving average price of $6.90. The company has a debt-to-equity ratio of 0.39, a quick ratio of 15.47 and a current ratio of 16.24. The stock has a market cap of $432.60 million, a price-to-earnings ratio of 6.50 and a beta of 1.62.

CryoPort (NASDAQ:CYRX - Get Free Report) last posted its quarterly earnings results on Tuesday, August 5th. The company reported ($0.29) earnings per share for the quarter, missing the consensus estimate of ($0.20) by ($0.09). CryoPort had a negative return on equity of 9.79% and a net margin of 37.21%.The business had revenue of $45.45 million during the quarter, compared to analysts' expectations of $41.74 million. CryoPort has set its FY 2025 guidance at EPS. Research analysts predict that CryoPort, Inc. will post -0.99 EPS for the current fiscal year.

Insiders Place Their Bets

In related news, CFO Robert Stefanovich sold 9,300 shares of the company's stock in a transaction on Tuesday, August 19th. The stock was sold at an average price of $8.67, for a total transaction of $80,631.00. Following the completion of the sale, the chief financial officer owned 207,213 shares in the company, valued at approximately $1,796,536.71. This represents a 4.30% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CEO Jerrell Shelton sold 151,304 shares of the company's stock in a transaction on Tuesday, June 17th. The shares were sold at an average price of $6.81, for a total value of $1,030,380.24. Following the sale, the chief executive officer owned 912,419 shares of the company's stock, valued at approximately $6,213,573.39. This trade represents a 14.22% decrease in their position. The disclosure for this sale can be found here. Insiders have sold 449,413 shares of company stock worth $3,160,008 over the last three months. Company insiders own 10.00% of the company's stock.

CryoPort Company Profile

Cryoport, Inc provides temperature-controlled supply chain solutions in biopharma/pharma, animal health, and human reproductive medicine markets in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. The company offers Cryoport Express Shippers; Cryoport ELITE -80°C Gene Therapy Shipper; Cryoport ELITE Cryosphere Shipper; Cryoport consulting services, including physical, thermal, and shipping qualifications of shipping systems and/or packaging to developing custom packaging solutions; and Cryoport bioservices, such as controlled temperature storage, fulfilment, kit production, secondary packaging, labelling of therapeutic products, and GMP raw materials storage services.